Do not give additional Elonva inj w/in the same treatment cycle; do not administer additional FSH-containing drugs after administration of Elonva prior to stimulation day 8. Not recommended for women w/ renal insufficiency; concomitant use w/ a GnRH agonist. Assess couple's infertility. Evaluate & correct hypothyroidism, adrenocortical insufficiency, hyperprolactinemia & pituitary or hypothalamic tumours in particular to women prior to treatment. Adhere to the recommended dose & treatment regimen, & carefully monitor ovarian response to reduce risk of OHSS. Assess ultrasonographically follicular development prior to therapy & at regular intervals during treatment. Increased risk of multiple & ectopic pregnancy, congenital malformations. Ovarian & other reproductive neoplasms (benign & malignant). Personal or family history of thromboembolic events, severe obesity or thrombophilia. May affect ability to drive or operate machinery. Lactation is not indicated during therapy. False positive hCG pregnancy result if administered during ovarian stimulation portion of the ART cycle.